Prognostic significance of c-Myc expression in soft tissue leiomyosarcoma

Modern Pathology

Volumn 22, Issue 11, 2009, Pages 1432-1438

  Tsiatis, Athanasios C ^a   Herceg, Megan E ^b   Keedy, Vicki L ^c   Halpern, Jennifer L ^b   Holt, Ginger E ^b   Schwartz, Herbert S ^b   Cates, Justin M M ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

C Myc; Immunohistochemistry; Leiomyosarcoma; prognosis

Indexed keywords

ADULT; ARTICLE; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MALE; ONCOGENE C MYC; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

EID: 70350643879     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.113     Document Type: Article

References (36)

1. Farshid G, Pradhan M, Goldblum J, et al. Leiomyosar-coma of somatic soft tissues: a tumor of vascular origin with multivariate analysis of outcome in 42 cases. Am J Surg Pathol 2002;26:14-24
2. Svarvar C, Bohling T, Berlin O, et al. Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group. Cancer 2007; 109:282-291
3. Coindre JM, Terrier P, Bui NB, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol 1996;14:869-877
4. Ren B, Yu YP, Jing L, et al. Gene expression analysis of human soft tissue leiomyosarcomas. Hum Pathol 2003;34:549-558
5. Ren B, Yu YP, Tseng GC, et al. Analysis of integrin alpha7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma. J Natl Cancer Inst 2007;99:868-880
6. Belkin AM, Stepp MA. Integrins as receptors for laminins. Microsc Res Tech 2000;51:280-301
7. Xiao J, Jethanandani P, Ziober BL, et al. Regulation of alpha7 integrin expression during muscle differentiation. J Biol Chem 2003;278:49780-49788
8. Knoepfler PS. Myc goes global: new tricks for an old oncogene. Cancer Res 2007;67:5061-5063
9. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002;2: 764-776
10. Shen J, Scotlandi K, Baldini N, et al. Prognostic significance of nuclear accumulation of c-myc and mdm2 proteins in synovial sarcoma of the extremities. Oncology 2000;58:253-260
11. Gamberi G, Benassi MS, Bohling T, et al. C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression. Oncology 1998;55: 556-563
12. Scionti I, Michelacci F, Pasello M, et al. Clinical impact of the methotrexate resistance-associated genes c-myc and dihydrofolate reductase (DHFR) in high-grade osteosarcoma. Ann Oncol 2008;19:1500-1508
13. Morrison C, Radmacher M, Mohammed N, et al. Myc amplification and polysomy 8 in chondrosarcoma: array comparative genomic hybridization, fluorescent in situ hybridization, and association with outcome. J Clin Oncol 2005;23:9369-9376
14. Schneider-Stock R, Boltze C, Jager V, et al. Elevated telomerase activity, c-MYC-, and hTERT mRNA expression: association with tumour progression in malignant lipomatous tumours. J Pathol 2003;199: 517-525
15. Fotiou SK, Tserkezoglou AJ, Mahera H, et al. Chromosome aberrations and expression of ras and myc oncogenes in leiomyomas and a leiomyosarcoma of the uterus. Eur J Gynaecol Oncol 1992;13:340-345
16. Jeffers MD, Richmond JA, Macaulay EM. Overexpres-sion of the c-myc proto-oncogene occurs frequently in uterine sarcomas. Mod Pathol 1995;8:701-704
17. Barrios C, Castresana JS, Kreicbergs A. Clinicopatho-logic correlations and short-term prognosis in muscu-loskeletal sarcoma with c-myc oncogene amplification. Am J Clin Oncol 1994;17:273-276
18. Maillet MW, Robinson RA, Burgart LJ. Genomic alterations in sarcomas: a histologic correlative study with use of oncogene panels. Mod Pathol 1992;5: 410-414
19. Shin DM, Gupta V, Donner L, et al. Aberrant oncogene expression in uncultured human sarcoma and melanoma. Anticancer Res 1987;7:1117-1123
20. Kempson RL, Fletcher CDM, Evans HL, et al. Vol 30 3rd series. Armed Forces Institute of Pathology: Washington, DC, 2001, 507pp
21. Greene FL, Page DL, Fleming ID, et al. (eds) AJCC Cancer Staging Manual 6th edn Springer Verlag: New York, 2002, 421pp.
22. Social security death index. http://www.genesearch.com/socialsecurity. htmlAccessed: 17 February, 2009
23. Kirkman TW. Statistics to use. http://www.physics.csbsju.edu/stats/1996
24. Therneau T, Lumley L. Survival: survival analysis, including penalised likelihood R package version 2.34-1 2008
25. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, 2008; http://www. R-project.org
26. Liu J, Burkin DJ, Kaufman SJ. Increasing alpha 7 beta 1-integrin promotes muscle cell proliferation, adhesion, and resistance to apoptosis without changing gene expression. Am J Physiol Cell Physiol 2008;294: C627-C640
27. Nawrotzki R, Willem M, Miosge N, et al. Defective integrin switch and matrix composition at alpha 7-deficient myotendinous junctions precede the onset of muscular dystrophy in mice. Hum Mol Genet 2003;12:483-495
28. Benaud CM, Dickson RB. Regulation of the expression of c-Myc by beta1 integrins in epithelial cells. Oncogene 2001;20:759-768
29. Marampon F, Bossi G, Ciccarelli C, et al. MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma. Mol Cancer Ther 2009;8:543-551
30. Marampon F, Ciccarelli C, Zani BM. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyo-sarcoma and in non muscle-derived human tumors. Mol Cancer 2006;5:31
31. Ponzielli R, Katz S, Barsyte-Lovejoy D, et al. Cancer therapeutics: targeting the dark side of Myc. Eur J Cancer 2005;41:2485-2501
32. Jain M, Arvanitis C, Chu K, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002;297:102-104
33. Jonkers J, Berns A. Oncogene addiction: sometimes a temporary slavery. Cancer Cell 2004;6:535-538
34. Xie XK, Yang DS, Ye ZM, et al. Recombinant antisense C-myc adenovirus increase in vitro sensitivity of osteosarcoma MG-63 cells to cisplatin. Cancer Invest 2006;24:1-8
35. de Nigris F, Balestrieri ML, Napoli C. Targeting c-Myc, Ras and IGF cascade to treat cancer and vascular disorders. Cell Cycle 2006;5:1621-1628
36. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 2006;16:318-330